CAS: 145100-51-2; 2-[n,N-Bis(Trifluoromethylsulphonyl)Amino]-5-Chloropyridine

相似化合物

145100-50-1 1353992-35-4 2365418-58-0

上下游产品

CAS号1072-98-6 2-氨基-5-氯吡啶 | CAS号358-23-6 三氟甲磺酸酐 | CAS号171568-44-8 ETHYL 4-((5,5-D... | CAS号181180-42-7 3,6-dihydro-2H-... | CAS号188975-30-6 3,6-二氢-2H-吡喃-4-... | CAS号185099-68-7 8-B°C-3-(三氟甲基磺酰... | CAS号122948-57-6 4-(三氟甲基磺酰氧基)-3-... | CAS号138647-49-1 3,6-二氢-4-[[(三氟甲... | CAS号170011-47-9 1,4-二氧螺[4.5]十-7... | CAS号122135-83-5 2-(三氟甲基磺酰氧)环己-1... | CAS号122135-84-6 ethyl 3-(triflu... | CAS号180691-65-0 3-(((三氟甲基)磺酰基)氧...

2-氨基-5-氯吡啶,三氟甲磺酸酐 反应生成2-[n,正双(三氟甲烷烷磺酰)氨基]-5-氯吡啶
参考文献:合成未成年人烟草生物碱金刚烷胺的两种构象受约束的类似物.
标题:合成未成年人烟草生物碱金刚烷胺的两种构象受约束的类似物.
摘要:已经制备了鸟嘌呤类似物螺[4-氮杂丹-1,2'-哌啶](7)和螺[6-氮杂丹-1,2'-哌啶](8).一系列的钯催化反应(其中分子内环化构成关键反应)被用于制备两种目标化合物.
Doi:10.1021/ol006056F

专利信息

专利号:US-7910623-B2
优先权日:2005-07-22
标 题 :Synthesis of scabronines and analogues thereof
发明人：DANISHEFSKY SAMUEL J; WATERS STEPHEN P
权利人:SLOAN KETTERING INST CANCER
摘要:A novel synthesis of scabronines, which are related to a broader class of angularly fused tricyclic diterpenoids known as cyathanes, is provided. Scabronine G, its methyl ester derivative, and other analogs have been shown to have neurotrophic activity. Therefore, these compounds are particularly useful in treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's diseases, etc. The invention provides for the synthesis of scabronines as well as analogs thereof. Pharmaceutical compositions and method of using the inventive compounds are also provided.

专利号:US-9994508-B2
优先权日:2012-12-11
标 题:Versatile and functionalised intermediates for the synthesis of vitamin D and novel vitamin D derivatives
发明人：LOPEZ PEREZ BORJA; SIGUEIRO PONTE RITA; MAESTRO SAAVEDRA MIGUEL A; MOURINO MOSQUERA ANTONIO
权利人:ENDOTHERM GMBH
摘要:Novel intermediates for the complete synthesis of vitamin D are provided that allow a great versatility of functional groups in the final vitamin derivatives. Vitamin derivatives that are epimeric in position 3 and vitamin derivatives with a wide range of functionalities in position 18, including compounds with isotopic labelling are provided.

专利号:US-6090810-A
优先权日:1995-09-01
标题:Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
发明人：KLEIN ELLIOTT S; JOHNSON ALAN T; STANDEVEN ANDREW M; BEARD RICHARD L; GILLETT SAMUEL J; DUONG TIEN T; NAGPAL SUNIL; VULIGONDA VIDYASAGAR; TENG MIN; CHANDRARATNA ROSHANTHA A
权利人:ALLERGAN SALES INC
摘要:Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

专利号:US-8637555-B2
优先权日:2003-10-31
标题:Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
发明人：SEMPLE GRAEME; SCHRADER THOMAS; SKINNER PHILIP J; COLLETTI STEVEN L; GHARBAOUI TAWFIK; IMBRIGLIO JASON E; JUNG JAE-KYU; LIANG RUI; RAGHAVAN SUBHAREKHA; SCHMIDT DARBY; TATA JAMES R
权利人:SEMPLE GRAEME; SCHRADER THOMAS; SKINNER PHILIP J; COLLETTI STEVEN L; GHARBAOUI TAWFIK; IMBRIGLIO JASON E; JUNG JAE-KYU; LIANG RUI; RAGHAVAN SUBHAREKHA; SCHMIDT DARBY; TATA JAMES R; ARENA PHARM INC; MERCK & CO INC
摘要:The present invention relates to certain tetrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. n nAlso provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.

专利号:US-5877207-A
优先权日:1996-03-11
标 题:Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
发明人：KLEIN ELLIOTT S; JOHNSON ALAN T; STANDEVEN ANDREW M; BEARD RICHARD L; GILLETT SAMUEL J; DUONG TIEN T; NAGPAL SUNIL; VULIGONDA VIDYASAGAR; TENG MIN; CHANDRARATNA ROSHANTHA A
权利人:ALLERGAN SALES INC
摘要:Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

专利号:US-2008227851-A1
优先权日:2007-03-12
标题 :Laulimalide and laulimalide analogs
发明人：WENDER PAUL A
权利人:WENDER PAUL A
摘要:Novel laulimalide analogs, methods for the treatment of proliferative disease and processes for the synthesis of laulimalide and novel laulimalide analogs are described.